Gold prices steady above $3,400/oz on rate cut bets; PCE data awaited
Eric Venker, President and COO of Roivant Sciences (NASDAQ:ROIV), sold 100,000 common shares of the company on June 20, 2025, for $11.45 each, totaling $1.15 million. The transaction occurred near the stock’s current trading price of $11.52, with analysts setting price targets ranging from $12 to $22. According to InvestingPro analysis, the company maintains a strong financial health score.
According to a Form 4 filing with the Securities and Exchange Commission, on the same day, Venker also exercised options to acquire 100,000 common shares at a price of $3.85, for a total value of $385000. The company, currently valued at $7.86 billion, holds more cash than debt on its balance sheet, demonstrating solid financial positioning.
Following the sale, Venker directly owns 1,462,223 shares of Roivant Sciences. He also directly owns 8,238,897 shares underlying stock options. Discover more insights about ROIV’s insider transactions and 10+ additional exclusive ProTips with a subscription to InvestingPro.
In other recent news, Roivant Sciences has been the focus of several investment firms following developments in its drug pipeline. Cantor Fitzgerald has reiterated its overweight rating on Roivant Sciences, highlighting the potential of brepocitinib, an oral TYK2/JAK1 inhibitor, in treating dermatomyositis (DM) and other conditions. The Phase 3 trial for brepocitinib in DM is expected to report results in the second half of 2025, with a potential launch in early 2027 if successful. H.C. Wainwright also maintained its buy rating and $18.00 price target, noting that the Phase 3 VALOR study results could significantly expand the market opportunity for brepocitinib. Guggenheim echoed this sentiment, maintaining a buy rating and $15.00 price target, and estimating that brepocitinib could generate over $1 billion in sales for DM if approved.
Additionally, Roivant’s subsidiary Pulmovant reported positive Phase 1 data for mosliciguat, an inhaled treatment for pulmonary hypertension, showing promising pharmacokinetic results without serious side effects. The company is conducting a Phase 2 trial to further evaluate mosliciguat’s potential. Furthermore, H.C. Wainwright reaffirmed its $18.00 price target after discussions with Roivant’s CEO, focusing on the company’s strategic involvement with Immunovant (NASDAQ:IMVT) and expansion into new therapeutic areas. These recent developments underscore Roivant Sciences’ ongoing efforts to advance its drug pipeline and explore new opportunities in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.